Published in JAMA Network Open, a new study offers surprising results about plasma transfusion effectiveness for women with PPH.
©chanawit - stock.adobe.com
Dutch investigators theorized that outcomes in new mothers would be better with initiation of plasma transfusion within 60 minutes of persistent postpartum hemorrhage (PPH). Findings from their new study, however, tell a different story.
Methods
Published in JAMA Network Open, the results are from a multicenter cohort study conducted in the Netherlands. The authors identified women in the transfusion strategies in women during major obstetric hemorrhage (TeMpOH-1) study, which retrospectively assessed transfusion strategies used in women during major obstetric hemorrhage. The cohort in the new analysis had persistent PPH, defined as PPH with at least 1000 mL of blood loss refractory to first-line interventions to control bleeding.
In the Netherlands, in women with PPH who are hemodynamically stable enough, uterine or internal iliac artery embolization is used before resorting to hysterectomy. If embolization is not available in an institution, it is common practice to transfer the patient to a nearby hospital with embolization facilities.
The current study included 1216 women (mean age 31.6 years) with PPH, of whom 932 (76.6%) delivered vaginally and 780 (64.1%) had PPH caused by uterine atony. The authors used time-dependent propensity score matching to select women who received plasma during the first 60 minutes of persistent PPH. Each woman was matched with a woman who had PPH of the same severity and received the same treatment but who had not received plasma at the moment of matching. Transfusions were not guided by coagulation tests.
The main outcomes were incidence of adverse maternal outcomes, defined as a composite of death, hysterectomy, or arterial embolization. Seven of the women (0.6%) died of PPH, 62 (5.1%) underwent hysterectomy, and 159 (13.1%) had uterine artery embolization.
Findings
Among women who received plasma during the first 60 minutes of persistent PPH, 114 could be matched with a comparable woman who had not received plasma at the moment of matching. Incidence of adverse maternal outcomes was similar between the women, with adverse outcomes recorded in 24 women (21.2%) who received early plasma transfusion and 23 women (19.9%) who did not receive early plasma transfusion (odds ratio 1.09; 95% CI 0.57-2.09). Results of sensitivity analyses were comparable to the primary results.
Conclusions
While the results do not support the authors’ original hypothesis, they said they should not be taken to indicate that plasma transfusion has no place in treatment of women with severe PPH. “Rather,” they said, “our study underlines the importance of developing tools to diagnose coagulopathy during persistent PPH. These tools may enable individualization of treatment of women with persistent PPH by identifying women who develop coagulopathy during persistent PPH.”
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More